Amcon Distributing Co: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Jul 18, 2023 and accepted by EDGAR at Jul 18, 2023, 16:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $696.5m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2022-10-01 to 2023-06-30 | $1.85bn | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $649.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2022-10-01 to 2023-06-30 | $1.72bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $46.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-10-01 to 2023-06-30 | $123.0m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $36.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-10-01 to 2023-06-30 | $99.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | $7.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-10-01 to 2023-06-30 | $18.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $2.4m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-10-01 to 2023-06-30 | $6.2m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-10-01 to 2023-06-30 | $4.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | $3.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-10-01 to 2023-06-30 | $8.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | $6.59 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-10-01 to 2023-06-30 | $14.56 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | $6.74 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-10-01 to 2023-06-30 | $14.78 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 598,590 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-10-01 to 2023-06-30 | 593,480 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-10-01 to 2023-06-30 | $9.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-04-01 to 2023-06-30 | $5.5m | us-gaap:PaymentsToAcquireProductiveAssets |
| Capital expenditure | 9 months2022-10-01 to 2023-06-30 | $6.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2023-04-01 to 2023-06-30 | $100.0k | us-gaap:PaymentsOfDividendsCommonStock |
| Dividends paid | 9 months2022-10-01 to 2023-06-30 | $3.4m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2023-06-30 | $739.0k | us-gaap:Cash |
| Current assets | At period end2023-06-30 | $255.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $368.7m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $87.0m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-06-30 | $12.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-06-30 | $2.7m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-06-30 | $100.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-23-011951. Last ingested by Listed: Oct 29, 2026, 16:33 ET. Listed shows no prices and gives no investment advice.